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The Impact of Perinatal Methamphetamine Exposure
on Infant Outcome
(Editor’s note: Dr. Rizwan Shah is a Clinical Associate
Professor of Pediatrics at the University of Iowa’s Carver
College of Medicine and directs the CAIRE Clinic at Blank
Children’s Hospital in Des Moines. Dr. Shah is a nationally
recognized authority on the pediatric effects of prenatal expo-
sure of the fetus to illicit drugs. We are grateful to her for
sharing her knowledge with us. FJZ)
The state of Iowa has been among the “leaders” in
methamphetamine abuse for the past decade. The
manufacturing, trafficking, and use of methamphet-
amine have resulted in increased drug convictions and
incarcerations. The Iowa Substance Abuse Reporting
System (SARS) registered an increase in methamphet-
amine use from 1% to 16% among substance abuse
treatment seekers in the past decade. Thirty percent of
the clients are women; 10% of these are pregnant.
A study of the prevalence of drug use among preg-
nant Iowa women in 1995-1996, reported a 4%
prevalence. Marijuana was most commonly abused,
followed by opioids, cocaine, and methamphetamine.
Prevalence was highest among 19 to 23 year olds, fol-
lowed by women age 24 to 27.1
A survey of Iowa hospitals done in 1998 to document
newborn screening practices revealed that of 1111 neo-
nates tested for illegal drugs (about 3% of Iowa births),
17% were positive.2 More recent data suggest metham-
phetamine abuse in 2 to 3% of pregnant Iowa women.
Maternal substance abuse is associated with multiple
risk factors, which can adversely affect infant outcomes.
An awareness of these risks helps healthcare providers
in planning appropriate interventions for both mother
and infant. Because of the scarcity of information avail-
able regarding the impact of drug exposure on infants
and children, professionals, as well as the lay public,
tend to draw conclusions based upon their own per-
ceptions of harm from drug exposure. Clinical data
presented here will, I hope, answer some often asked
questions regarding infants exposed to methamphet-
amine.
The CAIRE Clinic for the followup of drug exposed
infants and children at the Blank Children’s Hospital
evaluates more than 200 infants and children each year
due to drug exposure concerns. Infants are followed in
the clinic at regular intervals to assess developmental
outcomes. In addition, demographic information is
gathered during the first visit. Some families use our
clinic for routine healthcare visits. This has provided us
with longitudinal data on our patients. Here is what
our clinical experience tells us about this special popu-
lation of children.
1. Drugs of exposure.
An infant is often exposed to four drugs prenatally.
They are: tobacco, alcohol, marijuana, and one other il-
legal drug. Currently in 90% of our cases this drug is
methamphetamine.
2. Pattern of drug abuse.
Pregnant women using methamphetamine in early
pregnancy are more likely to continue using it in the
third trimester. A majority of pregnant women using
methamphetamine smoke cigarettes, and use alcohol or
marijuana or both during pregnancy.
3. Prenatal care.
Forty percent of methamphetamine using women
receive no prenatal care. This compares with 22% of
cocaine using women in our experience and with a gen-
eral rate in Iowa of no prenatal care of 2%.
4. Preterm birth.
Methamphetamine abusing women deliver preterm
one quarter of the time. This is similar to that in cocaine
abusing women and is 2-1/2 times as likely as in the
general Iowa population.
5. Infant outcomes.
Concerns are often expressed regarding the impact
of methamphetamine on fetal and infant growth. These
concerns stem in part from our knowledge of metham-
phetamine abusing adults who frequently lose weight.
2In our clinic population, 19% of methamphetamine ex-
posed and 30% of cocaine exposed infants were below
the 10th percentile for birth weight. Height was not af-
fected in either of the methamphetamine-exposed or
cocaine-exposed cohorts. Ten percent of methamphet-
amine exposed infants and 20% of cocaine-exposed
infants had head circumference of less than the 10th per-
centile.
Common Signs Noted in Infants Exposed
to Methamphetamine
I am often asked if I can recognize or separate a meth-
amphetamine-exposed infant from infants exposed to
other drugs. I cannot. The fact is that most drug-exposed
infants are born full term, look and act healthy, and leave
the hospital without being identified as being exposed
to drugs. The single most important clue to the identifi-
cation of the drug-exposed infant is the self-report of
drug use by the mother.
Neurobehavioral Indicators of Drug Exposure
In contrast to the opioid exposed neonate, the meth-
amphetamine-exposed neonate does not go through
drug withdrawal. The following signs can be noted in
the first few months of life. They are not invariably
present.
Lability of State
The infant shifts between deep sleep and frantic cry-
ing with an inability to return to a calm state even with
soothing measures.
Disorganized Suck and Swallow
The methamphetamine exposed full term infant has
the sucking abilities of a preterm infant. In our clinic
population, this has resulted in feeding difficulties in
more than one third of methamphetamine-exposed in-
fants. When recognized, this results in multiple
inappropriate changes of formula in the first few months
of life and the increased diagnosis of colic in infancy.
Sleep Problems
One of the early developmental tasks of the infant
brain is to regulate the quality and quantity of sleep.
Both of these functions can be adversely affected by
exposure to methamphetamine prenatally. Thirty-nine
percent of infants in our methamphetamine-exposed
cohort had sleep regulation difficulties. This figure is
similar to the 44% in our cocaine-exposed cohort. It
should be noted that sleeping difficulties in children
often reflect environmental factors.
Quality of Movement
Methamphetamine exposed infants show poor qual-
ity purposeful movements with or without the presence
of tremors.
The Neuromuscular Examination
Most methamphetamine-exposed infants have a nor-
mal examination. I have observed more hypertonicity
in cocaine-exposed infants. Some methamphetamine-
exposed infants have suffered intracranial bleeding
before birth. These infants have neurological signs in-
cluding seizures, apnea, and paralysis.
Management of Infants Exposed to
Methamphetamine
Infants exposed to methamphetamine prenatally do
not require medication for irritability or feeding diffi-
culties. Education of caregivers to provide consistency
and stability in the environment is essential. Healthcare
professionals need to monitor developmental mile-
stones and educate the caregiver in handling sleep and
feeding problems. If neuromuscular signs are present,
early intervention services should be implemented.
IT CANNOT BE EMPHASIZED ENOUGH THAT A
STABLE POSTNATAL ENVIRONMENT IS CRUCIAL
FOR THE OPTIMAL DEVELOPMENTAL OUTCOME
OF INFANTS AND CHILDREN PRENATALLY EX-
POSED TO DRUGS.
—Rizwan Shah, M.D.
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3Newborn Toxicology Screening
In a recent update the National Survey on Drug Use
and Health (NSDUH) reported that in 2002 and 2003,
4.3 percent of pregnant women aged 15 to 44 had used
illicit drugs in the past month. These drugs included
opiates, marijuana, cocaine, alcohol, hallucinogens, in-
halants, tranquilizers, stimulants, and sedatives. This
number is up from 3.8 percent of pregnant women in
2001. The rate of drug use for pregnant teenagers, 15 to
17, was higher still, upwards of 15 percent. The NSDUH
data also suggest that women increased their substance
use during the year after giving birth.
Increasing rates of substance abuse during pregnancy
translate into higher numbers of drug-exposed infants.
Iowa hospitals are experiencing this trend with an in-
creasing number of newborns being screened for
substances of maternal abuse. Prenatal drug exposure
poses several risks to the fetus and newborn. The drug(s)
may have a teratogenic effect on the developing fetus.
Abrupt cessation of maternal drug supply at delivery
may result in acute withdrawal in the newborn. There
may be long-term effects on neurodevelopment that al-
ter behavior and learning. If maternal substance abuse
is not identified prior to discharge of mother and baby,
the drug-exposed infant is also at high risk for abuse
and neglect.
For these reasons it is essential that newborns in Iowa
be appropriately screened for the presence of illegal
drugs. Screening for maternal substance abuse must
begin with thorough history taking. All pregnant
women should be questioned about their use of pre-
scribed and unprescribed drugs. Recent trends of drug
use in the United States suggest that the predisposition
for drug abuse is similar through all racial, economic,
and educational strata. Comprehensive screening of
newborns is not currently recommended due to con-
cerns of cost and privacy. Instead, infants are selectively
screened for the presence of drugs when the mother’s
history of drug use is confirmed or suspected or when
symptoms suggestive of withdrawal are present in the
newborn.
Several Iowa hospitals have developed protocols for
screening newborns based on the identification of clini-
cal and social risk factors known to be associated with
the presence of illegal drugs in infants. The unexplained
presence of one or more of the following risk factors is
an indication for toxicology testing.
Neonatal drug screens can reliably detect the pres-
ence of maternal drugs in newborn hair, serum, urine,
and meconium. Testing methods vary by institution. In
Iowa, urine and meconium sampling are the most fre-
CLINICAL RISK FACTORS
MOTHER
No prenatal care
Late prenatal care (first visit after 16 weeks’ gesta-
tion)
Poor prenatal care (4 visits or fewer)
Abruptio placentae
Seizures
Inadequate weight gain
Acute episode of hypertension
Out-of-hospital delivery
Precipitous labor and delivery (less than 3 hours
duration)
Presenting to the hospital in the second stage of
labor
Physical and/or behavioral characteristics of drug
use
INFANT
Stillbirth
Premature delivery <37 weeks’ gestation
Birth weight <10th percentile on GA assessment
Small head circumference
Congenital anomalies
Seizures
Physical and/or behavioral characteristics of drug
withdrawal
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quently performed. Urine testing is least expensive, but
it has limited sensitivity with a higher incidence of false-
negative results. The validity of urine testing depends
on the elimination half-life of the substance in question.
Even a drug with a long elimination half-life can only
be detected in urine for a maximum of three to four
weeks after use. Meconium testing is an effective tool
for verifying drug exposure in utero from the second
trimester (as early as 14-16 weeks’ gestation) to birth.
The procedure is more costly, but meconium testing has
the highest sensitivity for detecting exposure of all of
the substances studied. The limitation for using meco-
nium is the narrow time-frame for sampling. In order
for the test to be accurate, meconium must be collected
within the first one to two days of life or the first three
stools. Serum testing and neonatal hair analyses are not
routinely done in Iowa.
It is important that every institution have a proce-
dure for documenting “chain of custody” in handling
all specimens obtained for the purpose of newborn toxi-
cology testing. Coordinated follow up with hospital
social services and referral to the Department of Hu-
man Services should occur whenever prenatal drug
exposure is confirmed.
— Penny K. Smith, RNC
Nurse Clinician Specialist
Department of Pediatrics
(References available from the author on request)
SOCIAL RISK FACTORS
Admission of homelessness
Admission of substance abuse
Known history of maternal substance abuse
Known history of paternal substance abuse
Report of substance abuse by a third party
Incarceration
Maternal history of depression or major psychiatric illness
History of removal of other children to foster care
